Effect of Inadequate Empiric Antibacterial Therapy on Hospital Outcomes in SARS-CoV-2-Positive and -Negative US Patients With a Positive Bacterial Culture: A Multicenter Evaluation From March to November 2020

Laura Puzniak,1,2 Karri A. Bauer,1 Kalvin C. Yu,1 Pamela Moise,1 Lyn Finelli,1 Gang Ye,2 Carisa De Anda,1 Latha Vankeepuram,2 and Vikas Gupta2

1Merck & Co., Inc., Kenilworth, New Jersey, USA, and 2Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA

Background. Increased utilization of antimicrobial therapy has been observed during the coronavirus disease 2019 pandemic. We evaluated hospital outcomes based on the adequacy of antibacterial therapy for bacterial pathogens in US patients.

Methods. This multicenter retrospective study included patients with ≥24 hours of inpatient admission, ≥24 hours of antibiotic therapy, and discharge/death from March to November 2020 at 201 US hospitals in the BD Insights Research Database. Included patients had a test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a positive bacterial culture (gram-positive or gram-negative). We used generalized linear mixed models to evaluate the impact of inadequate empiric therapy (IET), defined as therapy not active against the identified bacteria or no antimicrobial therapy in the 48 hours following culture, on in-hospital mortality and hospital and intensive care unit length of stay (LOS).

Results. Of 438,888 SARS-CoV-2-tested patients, 39,203 (8.9%) had positive bacterial cultures. Among patients with positive cultures, 9.4% were SARS-CoV-2 positive, 74.4% had a gram-negative pathogen, 25.6% had a gram-positive pathogen, and 44.1% received IET for the bacterial infection. The odds of mortality were 21% higher for IET (odds ratio [OR], 1.21; 95% CI, 1.10–1.33; P < .001) compared with adequate empiric therapy. IET was also associated with increased hospital LOS (LOS, 16.1 days; 95% CI, 15.5–16.7 days; vs LOS, 14.5 days; 95% CI, 13.9–15.1 days; P < .001). Both mortality and hospital LOS findings remained consistent for SARS-CoV-2-positive and -negative patients.

Conclusions. Bacterial pathogens continue to play an important role in hospital outcomes during the pandemic. Adequate and timely therapeutic management may help ensure better outcomes.

Keywords. adequate therapy; antimicrobials; bacteria; COVID-19; empiric therapy; SARS-CoV-2.
antimicrobials in hospitals. In addition, the relevance of such studies to the COVID-19 pandemic, in which patients with SARS-CoV-2 constitute a substantial proportion of the hospitalized population at many institutions, has not been assessed.

We evaluated the impact of IET on clinical outcomes in hospitalized patients with positive bacterial cultures during the COVID-19 pandemic and compared outcomes associated with IET in SARS-CoV-2-positive vs SARS-CoV-2-negative patients. The inclusion of SARS-CoV-2-negative patients allowed us to provide contemporary insights into outcomes associated with IET exclusive of the complexities surrounding SARS-CoV-2 infections.

**METHODS**

**Study Design**

We conducted a multicenter, retrospective cohort analysis of data from 201 US medical facilities encompassed by the BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), which includes large and small medical care facilities throughout the United States (BD Insights Research Database, Becton, Dickinson & Company, Franklin Lakes, NJ, USA) [13–15]. The primary objective was to evaluate the impact of IET on outcomes (mortality and length of stay) in hospitalized patients with a positive bacterial culture overall and by SARS-CoV-2 testing result.

Eligible admissions were hospitalized adults (≥18 years of age) with a >1-day inpatient admission, ≥24 hours of antibiotic therapy, and a record of discharge or death between March 1, 2020, and November 28, 2020. Study inclusion required a SARS-CoV-2 test; samples for SARS-CoV-2 polymerase chain reaction or antigen testing had to be collected during the period between 7 days before admission and 14 days after admission, consistent with current definitions for non-hospital-onset COVID-19 [16]. A positive culture for gram-negative or gram-positive bacteria with susceptibility results was also required.

Bacterial culture sites included respiratory, blood, urine, skin/wound, intra-abdominal, and other specimens. Microbiology results likely associated with surveillance cultures (eg, nasal or rectal swabs) and environmental cultures were excluded by a previously described methodology that uses source, time of collection, microorganism type, and number of microorganisms in a culture to flag likely contaminated samples [17]. In analyses of outcomes by culture site, patients who had positive specimens from >1 culture site were included in analyses for each site.

The following bacteria with susceptibility results were included: gram-negative bacteria [Enterobacteriaceae [Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Citrobacter freundii, Proteus mirabilis, and Morganella morganii], Pseudomonas aeruginosa, Acinetobacter species [A. baumannii and A. baumannii/haemolyticus], and Stenotrophomonas maltophilia] and gram-positive bacteria [Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp. [E. faecalis, E. faecium]]. Polymicrobial findings were defined as >1 designated gram-positive or gram-negative bacterium obtained from any culture source during the admission.

Empiric antimicrobial therapy with an order for ≥24 hours was evaluated and categorized as adequate or inadequate. IET was defined as (a) antimicrobial therapy within 48 hours from culture collection that did not cover the bacteria and/or to which the bacteria had intermediate susceptibility or resistance or (b) no antimicrobial therapy prescribed within 48 hours from culture collection in a patient with a positive culture. Adequate empiric therapy (AET) was defined as antimicrobial therapy within 48 hours from culture collection that covered the bacteria and to which the bacteria were susceptible.

Outcome and epidemiological studies using this retrospective, deidentified data set were approved, and informed consent waived by the New England Institutional Review Board (Wellesley, MA, USA; IRB No. 120180023).

**Outcomes**

We evaluated in-hospital mortality, hospital length of stay (LOS), and intensive care unit (ICU) LOS in patients with adequate or inadequate therapy overall and by SARS-CoV-2 testing result. LOS was based on hospital admission, discharge, and transfer data and calculated as the difference between admission date and discharge date.

Maximum laboratory values recorded within the first 3 days of admission were used as a surrogate for admission period comorbidities, defined as underlying severe illnesses or conditions (Supplementary Table 1) [18]. We evaluated 6 comorbidities: renal insufficiency or failure, liver dysfunction, diabetes, sepsis, suspected heart failure or myocardial inflammation, and cytokine stimulation. Due to lack of timely device data to identify ventilator use, we used the following surrogate definition to imply ventilator use: (a) the patient was started on intravenous (IV)/IV push (IVP) sedation medications (propofol, lorazepam, midazolam, dexametomidine, or ketamine) or IV/IVP opioids (fentanyl, remifentanil, sufentanil, hydromorphone) with a duration ≥24 hours AND (b) at least 2 arterial blood gas results collected at least 24 hours apart (on the first day of sedation medication and a subsequent result 24 hours later).

**Statistical Analysis**

Baseline characteristics for patients receiving IET vs AET were evaluated by chi-square tests. In the exploratory analysis, we used chi-square tests (Fisher exact tests where appropriate) or t tests to evaluate the correlation between each outcome and each of the covariates. In the multivariable analysis, random-intercept logistic regression modeling was used for assessment of mortality, and generalized linear mixed model (GLMM) methods were used for evaluating hospital LOS and ICU LOS with hospital as random
effect. The following variables were included in these models: SARS-CoV-2 test result (positive or negative), empiric therapy (AET or IET), discharge month, culture source, age group, sex, SARS-CoV-2 test setting (admission [≤3 days postadmission] or nonadmission [>3 days postadmission]), *Candida albicans* test result (positive or negative), polymicrobial (>1 bacterium) findings, baseline comorbidities, ICU/ventilator criteria, hospital characteristics (bed size, facility type, teaching status), and geographic region based on US Census regions. All analyses were conducted using the Statistical Analysis System (SAS), version 9.4 (SAS Institute, Cary, NC, USA).

**RESULTS**

Of 1 976 567 admissions from 201 hospital facilities, 438 888 (22.2%) patients were tested for SARS-CoV-2 and 39 203 (8.9%) patients had a positive bacterial culture. Of these 39 203 patients, 3674 (9.4%) were positive for SARS-CoV-2 and 11 679 (29.8%) were in the ICU and/or met criteria for ventilator support. The mean (SD) age was 66.1 (16.7) years. Most patients (90.1%) were admitted to urban hospitals, and 56.7% of patients were admitted to hospitals with >300 beds (Supplementary Table 2). The largest proportions of patients were admitted to hospitals in the South Atlantic (19.6%) and East South Central (17.7%) regions.

Comorbidities were frequent in this patient population, particularly liver dysfunction (46.5%) and diabetes (43.3%). Overall, 83.7% of patients had 1 of the 6 specified comorbidities. Rates of comorbidities were higher in SARS-CoV-2-positive compared with SARS-CoV-2-negative patients (Table 1).

In the full patient cohort, positive cultures for gram-negative bacteria were about 3-fold more common than positive cultures for gram-positive bacteria (74.4% vs 25.6%) (Table 1). Polymicrobial findings were identified in 19.4% of patients; 11.3% had positive cultures for both gram-positive and gram-negative bacteria. No differences in gram-positive/gram-negative distribution or polymicrobial findings were observed between SARS-CoV-2-positive and -negative patients. The most common overall culture source was urine (52.8%), followed by blood (24.2%), skin (20.4%), respiratory (14.3%), intra-abdominal (1.7%), and other (3.2%; patients could have >1 source) (Supplementary Table 3).

Analysis of baseline characteristics found significant differences in the distribution of most characteristics by IET vs AET status (Table 1). A few notable differences are specifically related to the bacterial infections, including higher usage of IET in patients with gram-positive pathogens (65.1%), polymicrobial findings (52.1%), and respiratory isolates (64.9%).

**Impact of IET by SARS-CoV-2 Test Result**

During the time period of this study, 47.7% of SARS-CoV-2-positive and 43.8% of SARS-CoV-2-negative patients with positive bacterial cultures received IET. In observed data and univariate analyses, IET was associated with worse outcomes regardless of patient SARS-CoV-2 result (Table 2). Observed mortality rates in SARS-CoV-2-positive patients were 29.1% for IET vs 22.5% for AET (P < .001), and observed mortality rates in SARS-CoV-2-negative patients were 6.9% for IET vs 5.2% for AET (P < .001). IET was also associated with significantly longer hospital LOS vs AET in both SARS-CoV-2-positive and -negative patients and with significantly longer ICU LOS in SARS-CoV-2-negative patients (Table 2).

The effect of IET was retained in multivariable-adjusted models (Figure 1). The risk of mortality was increased to a similar extent with IET in both patients positive for SARS-CoV-2 (OR, 1.21; 95% CI, 1.02–1.43; P = .027) and those who were negative for SARS-CoV-2 (OR, 1.22; 95% CI, 1.11–1.33; P < .001). Compared with AET, IET was associated with significantly longer hospital LOS for both SARS-CoV-2-positive (estimated LOS, 18.7 days; 95% CI, 17.8–19.6 days; vs estimated LOS, 17.2 days; 95% CI,
Table 1. Clinical Characteristics by SARS-CoV-2 Status and Adequacy of Antibacterial Empiric Therapy

| Pathogen or Characteristic | Total       | SARS-CoV-2 Tested | SARS-CoV-2 Positive | SARS-CoV-2 Negative | Total       | SARS-CoV-2 Tested | SARS-CoV-2 Positive | SARS-CoV-2 Negative | Total       | SARS-CoV-2 Tested | SARS-CoV-2 Positive | SARS-CoV-2 Negative |
|----------------------------|-------------|-------------------|--------------------|--------------------|-------------|-------------------|--------------------|--------------------|-------------|-------------------|--------------------|--------------------|
|                            | Subtotal    | No. (% of Row)    | No. (% of Row)     | No. (% of Row)     | Subtotal    | No. (% of Row)    | No. (% of Row)     | No. (% of Row)     | Subtotal    | No. (% of Row)    | No. (% of Row)     | No. (% of Row)     |
|                            | P Value     |                   |                    |                    | P Value     |                   |                    |                    | P Value     |                   |                    |                    |
|                            | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Age group, y               |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| <56 (Q1)                   |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| 56-68 (median)             |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| >79                        |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| Sex                        | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Male                       |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| Female                     |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| ICU admission              | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Yes                        |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| No                         | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Comorbidity                | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Livedr dysfunction         |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| Diabetes                   | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Heart failure or myocardial inflammation | <.0001 |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Sepsis                     | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Renal insufficiency or failure | <.0001 |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Cytokine stimulation       | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Presence of any of the 6 specified comorbidities | <.0001 |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Yes                        | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| No                         | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| SARS-CoV-2 test result     | <.0001      |                   |                    |                    | N/A         |                   |                    |                    | N/A         |                   |                    |                    |
| Positive                   |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| Negative                   |             |                   |                    |                    |             |                   |                    |                    |             |                   |                    |                    |
| Bacteria                   | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Gram-positive              | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Gram-negative              | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Polymicrobial findings     | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Yes                        | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| No                         | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Bacteria source            | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Respiratory                | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Nonrespiratory             | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| Positive Canolda albicans test | <.0001 |                   |                    |                    | 0.0021      |                   |                    |                    | <.0001      |                   |                    |                    |
| Yes                        | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |
| No                         | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    | <.0001      |                   |                    |                    |

Abbreviations: AET, adequate empiric therapy; ICU, intensive care unit; IET, inadequate empiric therapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*P values indicate differences in distribution based on AET/IET status.
### Table 2. Outcomes by Adequate or Inadequate Empiric Therapy: Observed Data and Univariate Assessment

| Outcome                      | AET Total (n = 39 203) | AET SARS-CoV-2 Positive (n = 3674) | AET SARS-CoV-2 Negative (n = 35 529) |
|-------------------------------|------------------------|-----------------------------------|--------------------------------------|
| No. (%)                       | 21 098 (55.9)          | 1922 (52.3)                       | 19 986 (56.3)                       |
| Mortality, No. (%)            | 1476 (6.7)             | 433 (22.5)                        | 1042 (5.2)                          |
| Mean hospital LOS (SD), d     | 9.1 (9.0)              | 14.7 (14.1)                       | 8.6 (8.2)                           |
| Mean ICU LOS (SD), d          | 6.9 (8.6)              | 14.0 (13.8)                       | 5.8 (7.0)                           |

Abbreviations: AET, adequate empiric therapy; ICU, intensive care unit; IET, inadequate empiric therapy; LOS, length of stay; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*P* < .001 for IET vs AET for all outcomes except for SARS-CoV-2-positive ICU LOS (*P* = .265).

### Table 3. Clinical Characteristics and Outcomes: Observed Data and Univariate Assessment

| Pathogen or Characteristic     | All Patients | ICU Patients |
|--------------------------------|--------------|--------------|
|                                | No. (%)      | Mortality, No. (%) | Hospital LOS, Mean (SD), d | No. | LOS, Mean (SD), d |
| All                            | 39 203 (100) | 3051 (78)       | 10.2 (10.0)                  | 11 221 | 7.7 (9.3)       |
| Age group, y                   |              |                |                             |       |                |
| <56 (Q1)                       | 9984 (25.5)  | 568 (5.7)       | 11.0 (11.5)                  | 2888  | 9.0 (10.9)      |
| 56–68 (median)                 | 9822 (25.1)  | 824 (8.4)       | 11.2 (10.8)                  | 3271  | 8.3 (9.8)       |
| 68–79 (Q3)                     | 10 149 (25.9)| 893 (8.8)       | 10.2 (9.3)                   | 3016  | 7.1 (8.3)       |
| >79                            | 9248 (23.6)  | 766 (8.3)       | 8.4 (7.5)                    | 2046  | 5.5 (6.6)       |
| Sex                            |              |                |                             |       |                |
| Female                         | 21 072 (53.8)| 1403 (6.7)      | 9.4 (9.4)                    | 5494  | 6.8 (8.5)       |
| Male                           | 18 131 (46.3)| 1648 (9.1)      | 11.2 (10.6)                  | 5727  | 8.5 (10.0)      |
| ICU and/or ventilator criteria met | 11 679 (29.8)| 2395 (20.5)    | 16.0 (13.5)                  | 11 221 | 7.7 (9.3) |
| Comorbidity                    |              |                |                             |       |                |
| Liver dysfunction              | 18 221 (46.5)| 2359 (13.0)     | 12.5 (11.6)                  | 6979  | 9.0 (10.4)      |
| Diabetes                       | 16 960 (43.3)| 1944 (11.5)     | 12.3 (11.6)                  | 6203  | 8.9 (10.2)      |
| Heart failure or myocardial inflammation | 13 898 (35.5)| 2039 (14.7) | 12.3 (11.5)                  | 6102  | 8.3 (9.5)       |
| Sepsis                         | 12 838 (32.8)| 1981 (15.4)     | 12.3 (12.0)                  | 5928  | 8.3 (9.7)       |
| Renal insufficiency or failure | 11 145 (28.4)| 1860 (16.7)     | 13.3 (12.1)                  | 4857  | 8.8 (10.3)      |
| Cytokine stimulation           | 6959 (17.8)  | 1208 (17.4)     | 14.9 (13.8)                  | 3040  | 11.0 (11.7)     |
| Presence of any of the 6 specified comorbidities | 32 818 (83.7)| 2976 (9.1)    | 11.0 (10.5)                  | 10 492 | 7.9 (9.5) |
| No                             | 6385 (16.3)  | 75 (12)         | 6.5 (5.7)                    | 729   | 4.5 (5.7)       |
| SARS-CoV-2 test result         |              |                |                             |       |                |
| Positive                       | 3674 (9.4)   | 942 (26.8)      | 16.3 (15.0)                  | 1590  | 14.4 (13.8)     |
| Negative                       | 35 529 (90.6)| 2109 (5.9)      | 9.6 (9.1)                    | 9631  | 6.5 (7.8)       |
| Bacteria                       |              |                |                             |       |                |
| Gram-positive                  | 10 039 (25.6)| 898 (9.0)       | 11.0 (9.3)                   | 3021  | 7.3 (8.2)       |
| Gram-negative                  | 29 164 (74.4)| 2153 (74.4)     | 10.0 (10.3)                  | 8200  | 7.8 (9.7)       |
| Polymicrobial findings         |              |                |                             |       |                |
| Yes                            | 7608 (19.4)  | 815 (10.7)      | 14.1 (13.5)                  | 2853  | 10.0 (11.4)     |
| No                             | 31 597 (80.6)| 2 236 (71.7)    | 9.3 (8.8)                    | 8368  | 6.9 (8.3)       |
| Bacteria source                |              |                |                             |       |                |
| Respiratory                    | 5620 (14.3)  | 1370 (24.4)     | 17.4 (14.9)                  | 3821  | 12.5 (11.7)     |
| Nonrespiratory                 | 33 583 (85.7)| 1681 (5.0)      | 9.0 (8.4)                    | 7400  | 5.1 (6.5)       |
| Positive Candida albicans test |              |                |                             |       |                |
| Yes                            | 829 (2.1)    | 163 (19.7)      | 22.3 (17.3)                  | 434   | 13.7 (13.6)     |
| No                             | 38 374 (97.9)| 2888 (75.3)     | 10.0 (9.6)                   | 10 787 | 7.4 (9.0) |

Abbreviations: ICU, intensive care unit; LOS, length of stay; Q, quartile; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*P* < .001 for mortality, LOS, and ICU LOS for each characteristic except for gram-positive vs gram-negative bacteria (*P* < .001 for mortality and hospital LOS; *P* = .62 for ICU LOS).
16.4–18.1 days; \( P = .001 \) and SARS-CoV-2-negative patients (estimated LOS, 13.9 days; 95% CI, 13.4–14.4 days; vs estimated LOS, 12.2 days; 95% CI, 11.7–12.6 days; \( P < .001 \)). IET was also associated with significantly longer ICU LOS for SARS-CoV-2-negative patients (estimated LOS, 6.3 days; 95% CI, 5.8–6.8 days; vs estimated LOS, 5.7 days; 95% CI, 5.3–6.2 days; \( P < .001 \)), but not SARS-CoV-2-positive patients (estimated LOS, 10.8 days; 95% CI, 9.8–11.9 days; vs estimated LOS, 11.3 days; 95% CI, 10.2–12.4 days; \( P = .38 \)) (Figure 1).

**DISCUSSION**

In this study of 39,203 hospitalized US adults tested for SARS-CoV-2 with positive cultures for gram-negative or
Empiric Bacterial Therapy Amid COVID-19 • OFID • 7

Table 4. Adjusted Effect of IET on Mortality and LOS in Multivariable Models

| Characteristic                  | Mortality (n = 39,203) | Hospital LOS, d (n = 39,203) | ICU LOS, d (n = 11,221) |
|--------------------------------|------------------------|-------------------------------|-------------------------|
|                                | OR (95% CI)            | Estimated Mean (95% CI)       | Estimated Mean (95% CI) |
| Empiric therapy                |                         |                               |                         |
| AET                            | Ref                    | <.001                         | <.001                   | .397                    |
| IET                            | 1.21 (1.10–1.33)       | 16.1 (15.5–16.7)              | 8.2 (7.6–8.9)           |
| SARS-CoV-2 test result         | <.001                  | <.001                         | <.001                   |
| Negative                       | Ref                    | 13.0 (12.6–13.5)              | 6.0 (5.5–6.5)           |
| Positive                       | 4.04 (3.67–4.45)       | 18.0 (17.2–18.7)              | 11.0 (10.1–12.0)        |

Abbreviations: AET, adequate empiric therapy; ICU, intensive care unit; IET, inadequate empiric therapy; LOS, length of stay; OR, odds ratio; Ref, reference value; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*Other covariates or adjusting variables included discharge month, culture source, age group, sex, Candida albicans test status (positive or negative), polymicrobial (yes/no), baseline comorbidities, ICU or ventilator criteria met, hospital characteristics (bed size, facility type, teaching status), and geographic region based on US Census regions. Respiratory source (yes/no) was included in the LOS models but was not included in the mortality model because it did not improve the model fit, despite the fact that this variable significantly affected mortality in univariate assessment. One possible reason is that a highly correlated factor, such as ICU/ventilator status, accounted for part of its effect on mortality. Other reasons, such as confounding from unknown or unobserved factors, may also have played a role in the multivariable modeling analysis.

gram-positive bacteria, 44.1% of patients had IET within the 48 hours after culture collection. IET was associated with higher mortality rates and longer LOS compared with AET regardless of SARS-CoV-2 result, but mortality was much higher in SARS-CoV-2-positive patients. Our data indicate that underlying gram-positive and gram-negative bacteria continue to play an important role in hospital outcomes during the COVID-19 pandemic, and one with the potential to be adequately managed to help ensure more favorable outcomes. In addition to evaluating antimicrobial use during the unique time of the pandemic, this study expands the scope of previous IET studies by including multiple bacterial species and culture sites from a large number of hospitalized patients with diverse geographic representation, thereby allowing our findings to be generalized to hospital care throughout the United States. Inclusion of patients who were negative for SARS-CoV-2 allowed us to gain insights into antibiotic therapy patterns in patients being treated for standard conditions. The use of a hospital database allowed us to explore findings in a large, diverse patient population, but as with any database exploration, this study is not definitive. Rather, it should be viewed as a hypothesis-generating analysis that will hopefully help direct further research into this important topic.

Although patients who were positive for SARS-CoV-2 had higher mortality and longer LOS compared with SARS-CoV-2-negative patients, the relative benefit of adequate therapy for the bacterial infection was similar regardless of SARS-CoV-2 result: IET was associated with a ~20% increase in mortality and an additional 1.5 days in hospital LOS in both SARS-CoV-2-positive and -negative patients. In multivariable models, ICU LOS was not significantly associated with IET overall or in SARS-CoV-2-positive patients, possibly due to the impact of multiple comorbid conditions, including organ failure, which may have obscured the effect of IET in the ICU patient subgroup. However, IET was significantly associated with ICU LOS in SARS-CoV-2-negative patients. These patients may provide a truer estimate of the attributable burden of IET on ICU stay without the potentially confounding effect of COVID-19 and its sequelae.

We have shown previously that LOS is ~2-fold higher in SARS-CoV-2-positive or -negative patients with a non-SARS-CoV-2 pathogen (most frequently Enterobacterales spp.) [5]. These data indicate that COVID-19 patients require significant hospital resources, particularly when the admission is complicated by the presence of an additional pathogen. Because we excluded patients with hospital-onset SARS-CoV-2 (positive tests >14 days after hospital admission), our data primarily reflect patients with concomitant or post-SARS-CoV-2 bacterial infections. Despite higher mortality rates, which can shorten the period of hospital resource utilization, the burden of care was greater in SARS-CoV-2-positive patients, as indicated by hospital and ICU LOS, and further increased by IET. It should be noted that the mortality rate of ~25% in SARS-CoV-2 patients observed here, which is comparable to the 23.6% ICU mortality rate for US COVID-19 patients [19], was likely elevated due to the study’s requirement for a positive gram-negative or gram-positive bacterial culture. Other data from our database indicate that the overall COVID-19 mortality rate in all hospitalized patients over this time period was ~11% [18]. High mortality rates were also observed in patients with polymicrobial findings, respiratory specimens as a source of bacteria, a positive Candida albicans test, ICU admission or ventilator criteria, and comorbidities at admission.

Consistent with studies of COVID-19 patients [20–22], we found that patients with certain characteristics, including age and male sex, and comorbidities such as renal dysfunction, cardiovascular disease, and cytokine stimulation had higher mortality rates in univariate analyses. The increased mortality rates in patients with any of the 6 specified baseline comorbidities are particularly notable, even within a patient population that was primarily SARS-CoV-2 negative. This elevated risk may be due in part...
to the use of laboratory surrogates to identify underlying conditions, which could have potentially increased the selection of severely ill patients with acute damage to organ systems, but nevertheless highlights the potential role of comorbidities, which are common in patients with COVID-19 [23], in patient outcomes.

This study was designed so that only patients who received antibiotic therapy for ≥24 hours were included in the analyses. However, 30% of patients with a positive gram-positive or gram-negative bacterial culture did not receive antibacterial therapy within the first 48 hours of culture collection and were therefore categorized as receiving IET. Other studies have reported that delays in antibiotic treatment can negatively impact patient outcomes and costs [11, 24–27]. This study shows that delays are further exacerbated in the era of COVID-19 and could be an important contributor to IET, which is associated with increased mortality and hospital LOS.

In a prepandemic study, the mean laboratory turnaround times for bacterial identification and antimicrobial susceptibility test results in blood specimens were 1.8 and 2.7 days, respectively [28]. Given the significant impact of IET in the first 48 hours of culture collection, reducing delays in achieving effective pathogen-directed treatment remains a critical goal for the care of patients with bacterial infections. Treatment followed by de-escalation as part of an antimicrobial stewardship program may provide a reasonable alternative to delayed therapy [29].

Equally important, however, is the potential overuse of antibiotics in patients who do not have a documented bacterial infection. We and others have found that most patients with SARS-CoV-2 are treated with antibiotics, although bacterial infections are fairly rare [2–9]. Overuse of antibiotics is not unique to the pandemic: An analysis of 2015 data found that the use of antibiotics in patients without a positive urine or blood culture was common [30]. Nevertheless, this trend has been exacerbated by the influx of patients with SARS-CoV-2 infections, who are more likely to receive antibiotics than SARS-CoV-2-negative or -untested patients [5]. Future studies will be required to evaluate whether antimicrobial usage patterns will remain consistent or diminish as clinicians become more accustomed to coping with SARS-CoV-2 infections.

Limitations of the study include the use of institutional facilities as the source of SARS-CoV-2 and bacterial results. There was no central laboratory or uniform method of testing, which may have influenced the results. No case definition for COVID-19 disease was applied, consistent with current medical care practices, so it is possible that some patients with SARS-CoV-2 identified here were asymptomatic but admitted for other causes. Patients with gram-positive or gram-negative pathogens may also have lacked clinically significant infections, although our established algorithm [17] is designed to remove admissions with colonizing microbes from the analyses, and the poorer outcomes in patients receiving IET suggest that positive bacterial cultures were associated with clinically meaningful sequelae. Future analyses are planned to evaluate the impact of IET by culture source. Although we attempted to adjust for relevant factors as identified by our statistical model, it is possible that other factors beyond the scope of our database may have influenced patient outcomes. In particular, LOS and mortality associated with hospital-onset infections may be influenced by the timing of infection and by LOS before infection [31]; these factors were not evaluated in this analysis. Certain geographic areas may have been underrepresented by our database and larger hospitals in more urban areas may have been overrepresented, which could have potentially impacted antimicrobial prescribing practices and testing capabilities.

The data in our study indicate that the high burden of care for hospitalized patients with COVID-19 is further exacerbated by IET in the presence of a non-SARS-CoV-2 pathogen, and that IET is common in hospitalized patients with positive bacterial cultures. Although the ability of IET to negatively impact outcomes is well known [9–11], our findings serve as a valuable reminder that the importance of AET is heightened during times when hospital resources are stretched thin. In addition, our data indicate that IET affects patients with positive bacterial cultures from a number of sources, not just those involving bloodstream infections, which are typically more severe. We hope this study enables stewardship programs to educate and contain IET in hospitals, including the expanded use of rapid diagnostics and initial therapy with agents likely to provide adequate antimicrobial coverage for suspected gram-positive and gram-negative bacteria.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments
We thank Sharon L. Cross, PhD, Fusion MD Medical Science Network, Inc., for providing manuscript support with funding from Becton, Dickinson & Company.

Financial support. This work was supported by a grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, to Becton, Dickinson, and Company, Franklin Lakes, NJ, USA. Medical writing was supported by Becton, Dickinson & Company.

Potential conflicts of interest. L.P., L.F., K.A.B., P.M., and C.D.A. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and shareholders in Merck & Co., Inc., Kenilworth, NJ, USA. K.C.Y., G.Y., L.V., and V.G. are employees of Becton, Dickinson & Company, which was contracted by Merck to conduct the study. K.C.Y. and V.G. also own stock in Becton, Dickinson & Company.

Patient consent. Outcome and epidemiological studies using this retrospective, deidentified data set were approved and informed consent waived by the New England Institutional Review Board (Wellesley, MA, USA; IRB No. 120180023).

References
1. Clancy CJ, Nguyen MH. Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect? Clin Infect Dis 2020; 71:2736–43.
2. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 71:2459–68.
3. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021; 27:520–31.
4. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial superinfections among persons with coronavirus disease 2019: a comprehensive review of data from postmortem studies. Open Forum Infect Dis 2021; 8:XXX–XX.
5. Puzniak L, Finelli L, Yu KC, et al. A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19. BMC Infect Dis 2021; 21:227.
6. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42:84–8.
7. Karami Z, Knoop BT, Dofferhoff ASM, et al. Few bacterial co-infections but high fungal coinfections in COVID-19 patients: a multicenter retrospective cohort study in the Netherlands. Infect Dis (Lond) 2021; 53:102–10.
8. Vaughn VM, Gandhi T, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis 2021; 72:e533–41.
9. Karaba SM, Jones G, Helset T, et al. Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study. Open Forum Infect Dis 2020; 71:XXX–XX.
10. Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect Dis 2015; 15:395.
11. Bassetti M, Rello J, Blasi F, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents 2020; 56:106184.
12. Zasowski EJ, Bassetti M, Blasi F, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. Chest 2020; 158:929–38.
13. McCann E, Sririvasan A, DeRyke CA, et al. Carbapenem non-susceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis 2019; 5:XXX–XX.
14. Gupta V, Ye G, Olesky M, et al. National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States. Int J Infect Dis 2019; 85:203–11.
15. Tabak YP, Sririvasan A, Yu K, et al. Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: retrospective analysis of 2016–2017 data from US hospitals. Infect Control Hosp Epidemiol 2019; 40:1229–35.
16. National Healthcare Safety Network. Upcoming additional and modified fields for acute care COVID-19 module. 2020. Available at: https://www.cdc.gov/nhsn/pdfs/commup/email-upcomingfields-covid19-508.pdf. Accessed 18 December 2020.
17. Brossette SE, Hacek DM, Gavin PJ, et al. A laboratory-based, hospital-wide, electronic marker for nosocomial infection: the future of infection control surveillance? Am J Clin Pathol 2006; 125:34–9.
18. Finelli L, Gupta V, Petigara T, et al. Mortality among US hospitalized patients with SARS-CoV-2 infection in 2020. JAMA Netw Open 2021; 4:e216556.
19. Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care 2020; 24:285.
20. Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the U.S. coronavirus disease 2019 (COVID-19)-associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis 2021; 72:e206–14.
21. Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care 2020; 8:49.
22. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol 2020; 92:1875–83.
23. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:458–64.
24. Shorr AF, Micek ST, Welch EC, et al. Inappropriate antibiotic therapy in gram-negative sepsis increases hospital length of stay. Crit Care Med 2011; 39:46–51.
25. Zilberberg MD, Nathanson BH, Sulham K, et al. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study. Antimicrob Resist Infect Control 2017; 6:124.
26. Boxime NG, Berger A, Altincatal A, et al. Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious gram-negative bacterial infections. Am J Med Sci 2019; 357:103–10.
27. Lodise TP, Berger A, Altincatal A, et al. Antimicrobial resistance or delayed appropriate therapy – does one influence outcomes more than the other among patients with serious infections due to carbapenem-resistant versus carbapenem-susceptible Enterobacteriaceae? Open Forum Infect Dis 2019; 6:XXX–XX.
28. Tabak YP, Vankeerbare L, Ye G, et al. Blood culture turnaround time in U.S. acute care hospitals and implications for laboratory process optimization. J Clin Microbiol 2018; 56:e00500-18.
29. Liu P, Ohl C, Johnson J, et al. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established antimicrobial stewardship program. BMC Infect Dis 2016; 16:751.
30. Magill SS, O’Leary E, Ray SM, et al. Emerging Infections Program Hospital Prevalence Survey Team. Assessment of the appropriateness of antimicrobial use in US hospitals. JAMA Netw Open 2021; 4:e212007.
31. Barnett AG, Bayersmann J, Allgnol A, et al. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value Health 2011; 14:381–6.